Targeted Pulse Quiz: September 29

During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.

FDA clears Triton 1 robotic colonoscopy for screening and advanced therapy, backed by first-in-human data showing high detection rates and reduced clinician workload.

Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.

The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.

The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.

Phase 3 trial shows trastuzumab botidotin boosts PFS and response rates versus T-DM1 in pretreated HER2-positive metastatic breast cancer, with manageable ocular toxicity.

During a live event, Ruta Rao, MD, and participants discussed how toxicity history, rather than head-to-head trial data, drives the choice among 3 antibody-drug conjugates once the first one fails or becomes intolerable.

The B7-H3–targeted antibody-drug conjugate tambotatug pelitecan significantly reduced the risk of death in patients with small cell lung cancer.